Axon Enterprise (NASDAQ:AXON) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Axon Enterprise (NASDAQ:AXON) in a report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating and a $700.00 target price on the biotechnology company’s stock.

Several other analysts also recently commented on AXON. JMP Securities raised their price objective on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Northland Securities lifted their target price on Axon Enterprise from $365.00 to $550.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Needham & Company LLC upped their price target on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Robert W. Baird upped their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Finally, Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $500.00 to $700.00 in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $504.92.

Axon Enterprise Trading Up 2.7 %

Axon Enterprise stock opened at $577.34 on Wednesday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. Axon Enterprise has a 12-month low of $246.99 and a 12-month high of $698.67. The firm has a market capitalization of $44.03 billion, a price-to-earnings ratio of 149.18, a P/E/G ratio of 14.19 and a beta of 1.04. The firm has a 50 day moving average of $601.33 and a 200 day moving average of $445.99.

Insider Buying and Selling at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jeffrey C. Kunins sold 1,035 shares of Axon Enterprise stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $624.47, for a total transaction of $646,326.45. Following the transaction, the insider now directly owns 124,243 shares of the company’s stock, valued at approximately $77,586,026.21. This represents a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,545 shares of company stock worth $31,159,317 over the last ninety days. Company insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of large investors have recently bought and sold shares of the business. Range Financial Group LLC purchased a new stake in Axon Enterprise in the fourth quarter worth $291,000. Capital Market Strategies LLC grew its holdings in shares of Axon Enterprise by 1.0% in the fourth quarter. Capital Market Strategies LLC now owns 2,826 shares of the biotechnology company’s stock worth $1,680,000 after purchasing an additional 29 shares during the last quarter. Everence Capital Management Inc. lifted its holdings in Axon Enterprise by 14.0% during the 4th quarter. Everence Capital Management Inc. now owns 1,550 shares of the biotechnology company’s stock valued at $921,000 after buying an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its position in Axon Enterprise by 32.0% in the 4th quarter. GAMMA Investing LLC now owns 1,300 shares of the biotechnology company’s stock valued at $773,000 after buying an additional 315 shares during the period. Finally, Versant Capital Management Inc grew its stake in Axon Enterprise by 4,750.0% in the 4th quarter. Versant Capital Management Inc now owns 97 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 95 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.